Altimmune, Inc.

Good morning, ladies and gentlemen. Welcome to the Ultimate Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in listen-only mode. After this speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising that your hand is raised. As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Luis Zanec, Vice President of Investillations. Luis, you may begin.

Thank you, operator, and good morning, everyone. Thank you for joining us for Altamir's second quarter 2026 financial results and business update call. On today's call, you will hear from Jerry Durso, our Chairman and Chief Executive Officer, Dr. Christophe Arbet-Engels, Chief Medical Officer, , and Greg Weaver . Following management's prepared remarks, we'll open the line for questions. Our second quarter 2026 earnings release was issued this morning and can be found in the investor relations section of our website. Before we begin, I would like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for the purpose of of Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. Altamune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a review of the risk factors that could affect the company's future results and operations, we refer you to our SEC files. I also direct you to read the forward-looking statements disclaimer in our press release issued this morning. Any statements made on this call speak only as of today's date, August 12th, 2026, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur on or after today's date. As a reminder, this call is being recorded and will be available for audio replay on our website. With that, I'll now turn the call over to Jerry.

Good morning, everyone. Thank you for joining us today for our second quarter 2026 financial results and business update call. 2026 is proving to be a year of significant progress as Altimmune evolves into a late stage company dedicated to serious liver diseases. We've been laser focused on execution since the beginning of the year and believe we're well positioned to advance our strategy and deliver on our mission. Hemadutide is our foundation and our confidence and conviction in its potential continues to strengthen with the growing body of clinical evidence. We're building momentum across our Pembidutide franchise and are excited for the future. Let me take a minute to highlight our recent progress. Starting with MASH, last week we announced the initiation of the PERFORMA phase three trial as we began enrolling patients in the global program. We worked with urgency to get the trial started quickly, just three months after securing the financial resources to fund the study through the 52-week readout. were very encouraged by the start of the trial. Sites are being activated quickly, and we're seeing great engagement by the medical community about what Performa may mean for the MASH treatment landscape. There remains a significant unmet need in MASH. We believe PEMV with its balanced one-to-one glucagon and GLP agonism in a single molecule has the potential to offer a differentiated profile for MASH patients. Moving now to alcohol use disorder, or AUD. We were pleased to report positive top-line data from the Reclaim Phase II trial last month. Pembidutide delivered a very strong, statistically significant, and clinically meaningful reduction in heavy drinking days, which was the trial's primary endpoint. The study also met important secondary endpoints, including a two-level reduction in WHO risk drinking levels and zero heavy drinking days. It's important to note that either of these two measures are currently accepted as FDA registrational endpoints. The totality of the top line data from Reclaim strengthens our conviction in PEBI's potential in AUD. We're moving quickly to gather the full data from the trial, then prepare the data package to request an end of phase two meeting with the FDA to discuss next steps. These compelling data, which to our knowledge are the most robust presented in AUD, further strengthens the potential of Pembidutide as a differentiated therapy across serious liver diseases. The results from this trial are also meaningful for the AUD patient community, where Pemidutai could represent an important advancement in an area that has lacked innovation for the past two decades, and again, where a significant unmet need remains. There are approximately 12 million adults in the U.S. with moderate to severe AUD. It's well accepted that this AUD population is more likely to develop liver disease, We believe pembidutide is uniquely positioned to benefit these higher risk patients as its dual mechanism can address the totality of disease by reducing alcohol cravings while also providing a direct effect on the liver. This population could serve as a key commercial opportunity with substantial future sales potential. Pembidutide has the potential to help address the continual liver diseases we're targeting, MASH, AUD, and ALD. We've now delivered strong Phase II data and yet another indication, and we're well on our way towards building our Pembidutide liver franchise. We're committed to executing our strategy with speed and efficiency, and the significant progress we've made this year reflects that commitment. We remain laser-focused on executing on our goal of bringing Pembidutide to patients who may benefit from its promising and differentiated therapeutic profile and creating value for our shareholders. With that, I'll turn the call over to Christophe for a clinical update.